Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Revenue (2022 - 2025)

Arcutis Biotherapeutics has reported Revenue over the past 4 years, most recently at $125.5 million for Q4 2025.

  • Quarterly results put Revenue at $125.5 million for Q4 2025, up 80.94% from a year ago — trailing twelve months through Dec 2025 was $370.1 million (up 90.23% YoY), and the annual figure for FY2025 was $372.1 million, up 123.41%.
  • Revenue for Q4 2025 was $125.5 million at Arcutis Biotherapeutics, up from $99.2 million in the prior quarter.
  • Over the last five years, Revenue for ARQT hit a ceiling of $125.5 million in Q4 2025 and a floor of $725000.0 in Q3 2022.
  • Median Revenue over the past 4 years was $37.8 million (2024), compared with a mean of $44.3 million.
  • Biggest five-year swings in Revenue: surged 4037.93% in 2023 and later grew 28.8% in 2025.
  • Arcutis Biotherapeutics' Revenue stood at $3.0 million in 2022, then soared by 356.81% to $13.5 million in 2023, then surged by 412.79% to $69.4 million in 2024, then skyrocketed by 80.94% to $125.5 million in 2025.
  • The last three reported values for Revenue were $125.5 million (Q4 2025), $99.2 million (Q3 2025), and $81.5 million (Q2 2025) per Business Quant data.